Last reviewed · How we verify
Recombinant Antithrombin
Recombinant Antithrombin, marketed by Children's Hospital Los Angeles, is a therapeutic protein currently available in the market. The drug holds a key composition patent expiring in 2028, providing a period of exclusivity and potential market protection. The primary risk is the lack of disclosed revenue data, which may affect investment and market valuation assessments.
At a glance
| Generic name | Recombinant Antithrombin |
|---|---|
| Also known as | ATryn |
| Sponsor | Children's Hospital Los Angeles |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis (PHASE2)
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL) (PHASE2)
- Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients (EARLY_PHASE1)
- Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PHASE3)
- Understanding "Heparin Resistance" in Cardiac Surgery (PHASE1)
- Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery (PHASE4)
- Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO (PHASE4)
- Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Antithrombin CI brief — competitive landscape report
- Recombinant Antithrombin updates RSS · CI watch RSS
- Children's Hospital Los Angeles portfolio CI